Repligen Corp (RGEN): Long-Term Debt
$542.21M
As of 2025-12-31
$551.05M
As of 2026-06-30
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $542.21M | +3.2% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $525.57M | n/a | 2026-02-26, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Repligen Corp (RGEN) | 2025-12-31 | $542.21M | +3.2% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $72.14M | -0.3% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $72.44M | +0.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.14B | +42.3% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $1.65B | +18.9% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $54.28M | n/a |
| Agenus Inc (AGEN) | 2025-12-31 | $44.66M | +34.6% |
| Biogen Inc. (BIIB) | 2025-12-31 | $6.29B | -0.1% |
| Fennec Pharmaceuticals Inc. (FENC) | 2024-12-31 | $19.34M | -37.5% |
Compare RGEN, ADMA, TARS, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗